5 completed, 1 terminated, 1 unknown. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow lixisenatide: new trials by email Literature Review of lixisenatide trials Research Report on lixisenatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease Lixisenatide, placebo - Parkinson Disease | Phase 2 | Completed | University Hospital, Toulouse | 156 | 2018-06-13 | 2025-11-28 |
| Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients LIXISENATIDE AVE0010, metformin - Type II Diabetes Mellitus | Phase 2 | Terminated | Sanofi | 2 | 2015-04-01 | 2017-01-30 |
| Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People Lixisenatide, Placebo - Diabetes Mellitus, Gastroparesis | Phase 1 / Phase 2 | Unknown | Royal Adelaide Hospital | 30 | 2013-11-01 | 2015-10-29 |
| Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin Lixisenatide (AVE0010), Liraglutide, Insulin Glargine - Type 2 Diabetes Mellitus | Phase 2 | Completed | Sanofi | 142 | 2012-05-01 | 2016-10-14 |
| Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug) - Type 2 Diabetes Mellitus | Phase 2 | Completed | Sanofi | 323 | 2011-11-01 | 2017-02-10 |
| Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Lixisenatide (AVE0010), Pen auto-injector, Liraglutide - Type 2 Diabetes Mellitus | Phase 2 | Completed | Sanofi | 148 | 2010-08-01 | 2016-11-28 |
| Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus LIXISENATIDE (AVE0010) - Type 2 Diabetes | Phase 2 | Completed | Sanofi | 542 | 2006-02-01 | 2014-01-28 |
Diabetes Mellitus, Type 2 (5) · Diabetes Mellitus (1) · Gastroparesis (1) · Parkinson Disease (1)
Sanofi (5) · Royal Adelaide Hospital (1) · University Hospital, Toulouse (1)
Germany (3) · France (2) · Poland (2) · Romania (2) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Hungary (1) · Lithuania (1) · Mexico (1) · Russia (1)
PMID 20722676, PMID 23368510, PMID 25887358, PMID 27284114, PMID 35460043, PMID 38598572
2009 (1)